Blood Biomarkers for Use in Alzheimer Disease—Moving From “If” to “How?”

Blood-based biomarkers have the potential to revolutionize clinical practice and clinical trials in Alzheimer disease (AD). However, to date, this “holy grail” opportunity has not been realized owing to a broad range of issues, including the lack of a clearly defined context of use (COU), lack of standardization of methods, and numerous failures at replication. Recently, however, a shift in the paradigm has occurred, with my colleagues and I proposing specific COUs for blood-based biomarkers along with potential paradigms for advancing from discovery to clinic and potential acceptable standards.1,2

See the full article on JAMA

Share to...

you may also be interested in …

‘Blue Zones’ around the world offer keys to longevity

‘Blue Zones’ around the world offer keys to longevity

Andrea Rosso is interviewed for a Post Gazette series about blue zones and how they translate in Pittsburgh. The story discusses the concept of "blue zones," areas around the world with the longest-living populations, and explores how the lifestyle habits of these...

How your brain ages, and some ways aging might be slowed 

How your brain ages, and some ways aging might be slowed 

Thomas Kraynak's article on healthy brain aging is published to the Pittsburgh Post Gazette!  In the article, Thomas Kraynak reflects on his grandma's incredible sharpness well into her nineties, noting how she stood out against the usual decline seen in older folks....

Congratulations to eBrain’s Own Kailyn Witonsky!

Congratulations to eBrain’s Own Kailyn Witonsky!

We're excited to announce that Kailyn Witonsky, a valued member of the eBrain community, has successfully secured grant funding for her project. This achievement not only showcases her exceptional dedication and talent but also underscores the impact and importance of...